AstraZeneca News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Trading-Depot

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

30.12.19	AstraZeneca: Lynparza Approved In US For Pancreatic Cancer - Quick Facts (RTTNews)
23.12.19	AstraZeneca: US Approves Enhertu, China Approves Triple-combination For COPD (RTTNews)
20.12.19	AstraZeneca Divests Arimidex, Casodex Rights In Europe, Certain Other Countries (RTTNews)
18.12.19	AstraZeneca Says FDA Panel Backs Lynparza Use For Pancreatic Cancer (RTTNews)
03.12.19	AstraZeneca To Sell Rights To Seroquel, Seroquel XR In The US, Canada (RTTNews)
29.11.19	AstraZeneca: FDA Grants Priority Review For Imfinzi - Quick Facts (RTTNews)
26.11.19	Novoheart To Co-develop Human Heart-in-a-Jar Model Of Heart Failure With AZN (RTTNews)
22.11.19	FDA Approves AZN's Calquence, GLYC's Data To Be Delayed, ENLV Withdraws Offering (RTTNews)
17.11.19	AstraZeneca Announces New Data From Phase III DAPA-HF Trial (RTTNews)
15.11.19	AstraZeneca: European Commission Approves Qtrilmet For Type-2 Diabetes (RTTNews)
14.11.19	AZN:FDA Accepts Regulatory Submission For Selumetinib In Neurofibromatosis Type1 (RTTNews)
12.11.19	AstraZeneca Reports Positive TULIP 2 Trial For Anifrolumab To Treat SLE (RTTNews)
11.11.19	AstraZeneca: Roxadustat Phase III Pooled Analyses Show Positive Efficacy (RTTNews)
08.11.19	AZN' Roxadustat Rises Hb Levels For Chronic Kidney Disease Patients With Anaemia (RTTNews)
30.10.19	AstraZeneca Divests Rights To Seroquel, Seroquel XR In Europe And Russia (RTTNews)
29.10.19	AZN's POSEIDON Has Poise, MRTX On The Move, MOR Drops Atopic Dermatitis Trial (RTTNews)
28.10.19	AstraZeneca's Phase III POSEIDON Trial Meets Primary Endpoint (RTTNews)
24.10.19	AstraZeneca Q3 Profit Declines; Raises FY Product Sales Growth Outlook (RTTNews)
22.10.19	Odonate On The Move With CONTESSA, FDA Snubs CLSD, It's A Yes For AZN, VRTX (RTTNews)
21.10.19	AstraZeneca Announces Approval For Farxiga In The US - Quick Facts (RTTNews)
17.10.19	AstraZeneca: FDA Grants Priority Review For Trastuzumab Deruxtecan (RTTNews)
14.10.19	ImaginAb, AstraZeneca, Pfizer, Takeda Join To Develop CD8 ImmunoPET Technology (RTTNews)
04.10.19	AstraZeneca: FDA Approves Self-administration For Fasenra In Fasenra Pen (RTTNews)
01.10.19	AstraZeneca To Sell Commercial Rights For Losec To Cheplapharm - Quick Facts (RTTNews)
30.09.19	AstraZeneca: Tagrisso Shows 52% Reduction In Disease Progression In FLAURA Trial (RTTNews)
30.09.19	AstraZeneca, MSD Report Positive Results From Phase III Trial With Lynparza (RTTNews)
23.09.19	AstraZeneca: CHMP Recommends Qtrilmet For Approval In EU For Type-2 Diabetes (RTTNews)
16.09.19	AstraZeneca Announces Fast Track Designation For FARXIGA - Quick Facts (RTTNews)
09.09.19	AstraZeneca: Imfinzi Shows Improved, Durable Responses In Extensive-stage SCLC (RTTNews)
04.09.19	AstraZeneca Announces Approval For Tagrisso In China - Quick Facts (RTTNews)
02.09.19	AstraZeneca Reports Detailed Results From Phase III DAPA-HF Trial - Quick Facts (RTTNews)
29.08.19	AstraZeneca Reports Positive Top-line Results From TULIP 2 Trial - Quick Facts (RTTNews)
27.08.19	FDA Grants Fast Track Designation For AstraZeneca's FARXIGA - Quick Facts (RTTNews)
22.08.19	AstraZeneca's NEPTUNE Fails, Xtandi Gets Priority Review, SENS Makes Sense (RTTNews)
22.08.19	AstraZeneca: Roxadustat Approved In China For Non-dialysis-dependent Patients (RTTNews)
21.08.19	AstraZeneca: Phase III NEPTUNE Trial Of Imfinzi Fails To Meet Primary Goal (RTTNews)
20.08.19	AstraZeneca: Farxiga Meets Primary Endpoint In Phase III Trial - Quick Facts (RTTNews)
14.08.19	AstraZeneca Reports Breakthrough Therapy Designation For Calquence - Quick Facts (RTTNews)
09.08.19	AstraZeneca: Tagrisso Shows Positive OS Results In Phase III FLAURA Trial (RTTNews)
07.08.19	AstraZeneca, Merck Report Positive Phase III Trial Results Of Lynparza (RTTNews)
05.08.19	AstraZeneca: EU Approves Forxiga Label Update In Type-2 Diabetes - Quick Facts (RTTNews)
25.07.19	AstraZeneca Q2 Profit Falls; Reiterates FY19 Earnings Outlook - Quick Facts (RTTNews)
15.07.19	AstraZeneca: FDA Issues Response Letter On SNDA For Farxiga - Quick Facts (RTTNews)
12.07.19	AZN's Imfinzi Granted US Orphan Drug Designation For Small Cell Lung Cancer (RTTNews)
01.07.19	AstraZeneca: CHMP Advises Self-administration Option For Fasenra - Quick Facts (RTTNews)
19.06.19	AstraZeneca Receives Japanese Approval For Lung Disease Treatment (RTTNews)
18.06.19	AstraZeneca: EC Oks Lynparza As Maintenance Treatment For Ovarian Cancer (RTTNews)
17.06.19	AstraZeneca: Positive Results From Calquence Study In Relapsed Or Refractory CLL (RTTNews)
06.06.19	AstraZeneca Phase 3 ELEVATE-TN Trial Of Calquence In CLL Meets Primary Endpoint (RTTNews)
10.05.19	AstraZeneca Reports Results From Cardiovascular Safety Analyses On Roxadustat (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

14.04.25		NASDAQ 100-Papier AstraZeneca-Aktie: Mit dieser Dividende bereitet AstraZeneca Anlegern eine Freude
04.04.25		Verluste in New York: NASDAQ 100 letztendlich tiefrot
04.04.25		Schwache Performance in New York: NASDAQ 100-Anleger bekommen am Freitagnachmittag kalte Füsse
04.04.25		Schwacher Handel in New York: NASDAQ 100 am Mittag mit Kurseinbruch
04.04.25		Freitagshandel in New York: NASDAQ 100 beginnt die Sitzung weit in der Verlustzone
03.04.25		Börse New York: Letztendlich deutlicher Rückschlag für den NASDAQ 100
03.04.25		Schwache Performance in New York: NASDAQ 100 implodiert am Nachmittag
03.04.25		Zurückhaltung in New York: NASDAQ 100 tiefrot

14.04.25

NASDAQ 100-Papier AstraZeneca-Aktie: Mit dieser Dividende bereitet AstraZeneca Anlegern eine Freude

04.04.25

Verluste in New York: NASDAQ 100 letztendlich tiefrot

04.04.25

Schwache Performance in New York: NASDAQ 100-Anleger bekommen am Freitagnachmittag kalte Füsse

04.04.25

Schwacher Handel in New York: NASDAQ 100 am Mittag mit Kurseinbruch

04.04.25

Freitagshandel in New York: NASDAQ 100 beginnt die Sitzung weit in der Verlustzone

03.04.25

Börse New York: Letztendlich deutlicher Rückschlag für den NASDAQ 100

03.04.25

Schwache Performance in New York: NASDAQ 100 implodiert am Nachmittag

03.04.25

Zurückhaltung in New York: NASDAQ 100 tiefrot

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Logitech Intl	61.88	5.60 %	K V
UBS Group	24.21	4.40 %	K V
Kuehne+Nagel Int	187.50	3.68 %	K V
Alcon	77.94	3.01 %	K V
CieFinRichemont	143.80	2.39 %	K V
Swiss Life Hldg	792.00	0.38 %	K V
Zurich Insur Gr	566.00	0.28 %	K V
Novartis	90.90	0.24 %	K V
Swisscom	536.50	-0.19 %	K V
Givaudan	3’775.00	-0.58 %	K V

AstraZeneca Aktie VALOR 163523 / ISIN US0463531089

Nachrichten zu AstraZeneca PLC (spons. ADRs)

Aktien Top/Flop

AstraZeneca Peer Group Nachrichten

Meistgelesene Nachrichten